RXi Pharmaceuticals Corp CEO Buys $5,880 in Stock (RXII)
RXi Pharmaceuticals Corp (NASDAQ:RXII) CEO Geert Cauwenbergh acquired 2,000 shares of RXi Pharmaceuticals Corp stock on the open market in a transaction that occurred on Wednesday, June 4th. The shares were purchased at an average price of $2.94 per share, for a total transaction of $5,880.00. Following the completion of the purchase, the chief executive officer now directly owns 23,100 shares in the company, valued at approximately $67,914. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
RXi Pharmaceuticals Corp (NASDAQ:RXII) traded up 2.10% during mid-day trading on Thursday, hitting $2.92. 46,717 shares of the company’s stock traded hands. RXi Pharmaceuticals Corp has a 52-week low of $2.55 and a 52-week high of $6.84. The stock has a 50-day moving average of $3.18 and a 200-day moving average of $3.95. The company’s market cap is $41.0 million.
RXi Pharmaceuticals Corp (NASDAQ:RXII) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.32) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.31) by $0.01. On average, analysts predict that RXi Pharmaceuticals Corp will post $-0.89 earnings per share for the current fiscal year.
A number of research firms have recently commented on RXII. Analysts at Laidlaw initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday. They set a “buy” rating and a $8.00 price target on the stock. Separately, analysts at Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock. Finally, analysts at HC Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a development-stage company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.